Biote heads into its third-quarter report with almost no benefit of the doubt left. Last quarter, management abandoned its long-repeated promise of a second-half return to year-over-year procedure growth. It cut full-year guidance sharply as fallout from its voluntary hormone-pellet recall ran deeper and longer than expected. The stock has since lost nearly 40% of its value. This report is the first real test of whether the reset was conservative enough, or whether the floor is still shifting.

The Street is looking for a loss of about 5 cents a share on revenue of roughly $44.0 million. That would be an 8.3% decline from the $48.0 million posted a year ago and a sharp reversal from the 22 cents earned in the same quarter last year. The whisper number sits slightly better at a 3-cent loss. That hints that some traders see room for a modest beat on cost control, though the gap is too small to signal real optimism. The more telling detail is that the revenue forecast is essentially flat with the $44.2 million reported last quarter. Management framed the back half as a period of sequential improvement, so a flat quarter would technically disappoint that narrative, even if it lands on consensus.

Guidance frames the math. Biote now expects 2026 revenue above $175 million, down from above $190 million, and adjusted EBITDA above $25 million, down from above $38 million. When the cut came, the full-year consensus still sat near $190.6 million, so estimates needed a hard reset. A run rate around $44 million per quarter annualizes just above the new revenue floor. That suggests the company has left itself little cushion, and any shortfall in the fourth quarter would put the target at risk.

The operating story hinges on margins and the salesforce. Management said supply from its Asteria subsidiary is now fully restored and inventory has normalized. Asteria supplied only about 30% of shipped pellets in the second quarter, versus more than half late last year, and management said the mix would improve in the third quarter. That matters because expensive third-party pellets, along with recall costs, dragged gross margin down to 65.4% from nearly 72% a year earlier. A visible rebound in gross margin would be the clearest proof that the supply fix is flowing to the bottom line. The other swing factor is SG&A. It jumped to $32.4 million on legal costs, and with most legal matters now settled, it should fall meaningfully. If adjusted EBITDA margin cannot recover from last quarter's 12.6% despite lower legal bills and better pellet mix, the reduced EBITDA target will start to look shaky.

Demand indicators deserve equal scrutiny. Clinic attrition has been stuck in the high single digits for a year. New-clinic ramps slowed because reps were diverted to service recall-affected accounts. New CEO Bob Peterson's second phase of the turnaround centers on salesforce productivity and accountability, so evidence of improving clinic activity or any dent in attrition would carry weight. Dietary supplements have been a steady performer but slowed to 5.7% growth. Holding the mid-to-high single digit pace management reaffirmed would help offset procedure weakness. Cash rose to $11.2 million, but operating cash flow turned negative, and a return to positive cash generation would ease balance sheet worries, particularly with management now openly weighing acquisitions.

Sentiment has soured noticeably, with bearish readings climbing to about 70% from roughly 53% before the last report. The stock trades at $1.15, far below its 200-day average near $1.86 and close to the $1.00 low of its post-earnings range. That leaves expectations depressed, but not necessarily cheap if the guide proves too generous. The deciding question is simple. Biote needs to show that the second-quarter trough was the bottom, with recovering margins and stable demand, rather than one more step in a recall-driven slide.